The global market for Cancer Cachexia was valued at US$2.7 Billion in 2024 and is projected to reach US$3.7 Billion by 2030, growing at a CAGR of 5.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Advancements in the understanding of cancer cachexia's underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.
The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients' genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.
Global Cancer Cachexia Market - Key Trends & Drivers Summarized
Cancer cachexia is a multifactorial syndrome characterized by severe body weight loss, muscle wasting, and anorexia, significantly impacting the quality of life and survival rates of cancer patients. Unlike general malnutrition, cancer cachexia is driven by complex metabolic changes and inflammation associated with the tumor and the body's response to it. This syndrome leads to a negative protein and energy balance, which is not easily reversed by conventional nutritional support. Cancer cachexia therapeutics are focused on addressing the complex and debilitating syndrome of cancer cachexia, characterized by severe weight loss, muscle atrophy, and anorexia in cancer patients. This condition significantly impacts patient quality of life, treatment efficacy, and overall prognosis. Unlike general malnutrition, cancer cachexia is driven by a combination of factors including systemic inflammation, metabolic dysregulation, and hormonal changes that lead to a negative protein and energy balance. Traditional nutritional support alone is insufficient, necessitating the development of targeted therapeutics. Current approaches in cancer cachexia therapeutics include anti-inflammatory agents, appetite stimulants, anabolic steroids, and agents that modulate metabolic pathways to preserve muscle mass and improve patient outcomes.Advancements in the understanding of cancer cachexia's underlying mechanisms have led to the identification of several promising therapeutic targets. For instance, drugs targeting pro-inflammatory cytokines such as TNF-alpha and IL-6 are being investigated for their potential to reduce systemic inflammation. Additionally, ghrelin agonists and other appetite stimulants aim to counteract anorexia and improve caloric intake. Anabolic agents such as selective androgen receptor modulators (SARMs) are being explored to promote muscle protein synthesis and prevent muscle wasting. Furthermore, combination therapies that address multiple aspects of cachexia simultaneously are under development, offering a more comprehensive approach to treatment. These advancements reflect a growing recognition of the need for multifaceted strategies to effectively combat this multifactorial syndrome.
The growth in the cancer cachexia therapeutics market is driven by several factors, including the rising prevalence of cancer, increased awareness of the condition, and ongoing advancements in therapeutic research. The global increase in cancer cases naturally leads to a higher incidence of cachexia, highlighting the urgent need for effective treatments. Greater awareness among healthcare providers and patients about the significant impact of cachexia on cancer treatment outcomes has spurred demand for specialized therapeutics. Continuous research and development efforts are yielding new therapeutic candidates and optimizing existing ones, further propelling market growth. Additionally, supportive government policies and funding for cancer research are facilitating the development and approval of novel treatments. The shift towards personalized medicine, with therapies tailored to individual patients' genetic and metabolic profiles, is also expected to drive the adoption of more targeted and effective cachexia treatments. Overall, the cancer cachexia therapeutics market is poised for significant expansion as new therapies emerge and existing ones are refined to better address this challenging condition.
Scope of the Study
The report analyzes the Cancer Cachexia market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Therapeutics (Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics); End-Use (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Progestogens Therapy segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 5.9%. The Corticosteroids Therapy segment is also set to grow at 5.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $985.5 Million in 2024, and China, forecasted to grow at an impressive 7.6% CAGR to reach $314.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AstraZeneca PLC, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Charles River Laboratories International, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cancer Cachexia Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Cachexia Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cancer Cachexia Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 50 major companies featured in this Cancer Cachexia market report include:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Charles River Laboratories International, Inc.
- Aphios Corporation
- Fresenius SE & Co. KGaA
- AbbVie, Inc.
- AVEO Pharmaceuticals, Inc.
- AAVogen, Inc.
- Immuneering
- Caelus Health
- AliveGen USA
- Endevica Bio
- Extend Biosciences
Table of Contents
I. METHODOLOGYMII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Charles River Laboratories International, Inc.
- Aphios Corporation
- Fresenius SE & Co. KGaA
- AbbVie, Inc.
- AVEO Pharmaceuticals, Inc.
- AAVogen, Inc.
- Immuneering
- Caelus Health
- AliveGen USA
- Endevica Bio
- Extend Biosciences
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 255 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.7 Billion |
| Forecasted Market Value ( USD | $ 3.7 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
